Equity Overview
Price & Market Data
Price: $1.10
Daily Change: -$0.02 / 1.82%
Daily Range: $1.09 - $1.15
Market Cap: $25,310,780
Daily Volume: 366,179
Performance Metrics
1 Week: -0.88%
1 Month: 59.13%
3 Months: 41.25%
6 Months: 42.12%
1 Year: -60.90%
YTD: -64.13%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.